A Wonder Drug in the Arsenal against COVID - 19: Medication Evidence from Ivermectin
B. Suresh Kumar, Madhan Jeyaraman, Rashmi Jain, Talagavadi Channaiah Anudeep
Journal of Advances in Medicine and Medical Research · pp. 30–37 · Published 6 Jul 2020
10.9734/jammr/2020/v32i1030512Abstract
Ivermectin, an FDA approved broad-spectrum anti-parasitic agent has been recently reported to show an inhibitory activity against SARS-CoV-2 in an in-vitro study. This antiviral response has rendered it as a potential drug to be repurposed for COVID-19. Previously, ivermectin had showed inhibitory activity against RNA viruses in-vitro and DNA viruses in-vitro and in-vivo respectively. Much of its characterization has been related to SARS-CoV wherein viral proteins interacting with IMPα/β1 (Importins) were proposed to enhance the viral infectivity. These documentations serve as a ray of hope for considering ivermectin in treating COVID-19 due to its suggested nuclear transport inhibitory mechanism. Importantly, these recent findings warrant detailed investigations for understanding its benefit in terms of efficacy and safety in COVID-19 patients. This review article throws light on the current consensus in this regard.
Cited by 6
6 citations reported by external sources — individual citing-article records aren't available to list yet.
Related research
- Anthelmintic Activity, Acute Toxicity of Anacardium occidentale L. (Anacardiaceae) on Onchocerca ochengi and Caenorhabditis elegans — shares topic coverage
- Seasonal Variations in Biting Density and Infectivity of Simulium damnosum Complex in Ezeagu and Oji-River Local Government Areas of Enugu State, Nigeria — shares topic coverage
- The Demirci Phenomenon: A Novel Finding of Ivermectin Molecules on Eyelash and Demodex Folliculorum in the Lipid Environment — shares topic coverage
- HPLC, Densitometric and Visible-Spectrophotometric Determination of Triclabendazole and Ivermectin — shares topic coverage
- Successful Management of Staphylococcal Dermatitis in a Dog: A Case Report — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
6
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.